immune respo. hot !
Thread abonnieren
|
--button_text--
interessant
|
|
witzig
|
|
gut analysiert
|
|
informativ
|
0
17:06:32 25 0,014++++++++++++++++++
15:37:28 350.000 0,015
13:21:29 50.000 0,014
11:31:48 4.500 0,014
10:38:01 120.000 0,014
09:02:27 390.000 0,01
sind zwar geringe umsätze aber da sind doch bestimmte mächte am start,,,,,
bei solchen kursen ist doch leicht was hin zubekommen wie man will,,
schauen wir mal ob man was ändern kann,,,stell jetzt ne order rein 100 st,für 10euro ja genau ha ha
Optionen
0
CEOs of the American Stock Exchange, London Stock Exchange, Borsa Italiana to Kick Off EQUITIES Transatlantic Corporate Conference
2006-09-11 19:50 ET - News Release
Also News Release (U-AVMD) ADVANCED MEDICAL INSTITUTIONS
Also News Release (U-CGLD) CAPITAL GOLD CP
Also News Release (U-ISO) ISCO INTL INC
LOS ANGELES, CA -- (MARKET WIRE) -- 09/11/06
EQUITIES Magazine proudly announces its first-ever Transatlantic Corporate Conference, aimed at bringing together American small-cap companies and European investors. This exciting event will also be Webcast at http://www.visualwebcaster.com/equitiesmag/amex2006/event.html
An Investment Bridge To Europe:
EQUITIES Transatlantic Conference will begin on September 15 at the American Stock Exchange in New York City, where a select group of emerging growth companies will present to a sophisticated audience of brokers, fund managers, investment professionals and active retail investors. The keynote speaker for the event will be AMEX CEO Neal Wolkoff, followed by Senior VP of Equities John McGonegal. These promising public companies will then travel to the London Stock Exchange on the 18th, where they will be greeted by keynote speaker Martin Graham, Head of the AIM market. The conference will finish on the 20th at the Borsa Italiana stock exchange in Milan, with keynote speaker Lodovico Rosnati, Director of Equities Markets.
Presenting Companies
Of the 12 exciting companies presenting, four of these promising public companies are:
-- Advanced Medical Institute, Inc. (PINKSHEETS: AVMD) Las Vegas, NV --
operates a chain of medical clinics for the treatment of sexual dysfunction
in men and women, primarily in Australia. It provides medical services,
pharmaceuticals, and associated support services. The company offers
various treatment options, which include injections, lozenges, tablets, and
nasal delivery systems for the treatment of erectile dysfunction; and
injection, lozenges, and nasal spray delivery systems for the treatment of
premature ejaculation. As of September 30, 2005, it operated 17 clinics
and a centralized call center. Advanced Medical Institute is based in
Alexandria, Australia.
-- Capital Gold Corporation (OTCBB: CGLD) (TSX: CGC) New York City, NY --
engages in the exploration for gold and other minerals primarily in Mexico.
The company, through its wholly owned subsidiary, Oro de Altar S. de R. L.
de C.V. and its affiliate, Minera Santa Rita S. de R.L. de C.V., owns 16
mining concessions, known as El Chanate concessions, located in Altar,
Sonora, totaling approximately 3,544 hectares. It also has a lease on
surface property for mining the Chanate gold deposit, which consists of 466
hectares in Altar, Sonora. Further, the company owns or leases claims and
properties located in Lake County, Colorado.
-- The Immune Response Corp. (OTCBB: IMNR) Carlsbad, CA -- is developing
its lead immune-based therapeutic candidates: NeuroVax (TM) targeting
multiple sclerosis and IR103 for treatment of HIV infection. Both in Phase
II, designed to stimulate pathogen-specific immune responses to slow or
halt rate of disease progression. NeuroVax, based on IMNR's patented T-
cell receptor peptide technology, shows potential in treating relapsing
forms of MS. This patented whole-inactivated virus technology was co-
invented by Dr. Jonas Salk.
-- ISCO International (AMEX: ISO) Elk Grove Village, IL -- ISCO
International, Inc. is a leading global supplier of radio-frequency
management and interference-control systems for the wireless
telecommunications industry. By integrating state-of-the-art filtering,
duplexing and low noise amplifier technology, we improve the performance of
new and existing cellular deployments. ISCO products focus on software-
based, adaptive filtering solutions targeted at increasing the performance
of CDMA and WCDMA wireless systems worldwide.
Transatlantic Conference Sponsors include:
Marsten Webb International, an international corporate communications firm which offers an unrivaled knowledge of markets and media throughout the globe; Richardson & Patel, a fast-growing, bi-coastal business law firm dedicated to helping emerging growth companies get the legal expertise they need; Bankside, a London-based public relations consultancy firm with a detailed knowledge of overseas and dual listing; Bigdough, an innovative provider of capital markets contact and ownership data; Onstream Media Corporation, an online service provider of live and on-demand, rich media communications, specializing in online audio and video corporate communications; and Interbank FX, an online currency trading firm focused on providing direct access and the latest trading technology to its worldwide customers.
About EQUITIES Global Communications, Inc.
EQUITIES Magazine
EQUITIES Global Communications, Inc. is a privately held corporation based in Los Angeles, CA. EQUITIES Magazine is written in a no-holds-barred style developed by its award-winning editor Robert J. Flaherty -- a legend in financial journalism. Flaherty is considered one of the nation's most outstanding investigative reporters on undiscovered, emerging and middle-market companies, and was previously named "one of the most influential journalists" by The Journal of Financial Reporting. Covering the most exciting companies in the small and mid-cap markets, EQUITIES' readers include some of the financial community's most savvy and respected investment professionals -- including corporate executives, market makers, traders, fund managers, institutional investors, portfolio managers, stockbrokers, analysts and sophisticated individual investors. In addition, EQUITIES Magazine has developed the most comprehensive investor awareness programs on the market, developing strategic marketing campaigns to help expose promising public companies to the investor marketplace. Of these programs include our EQUITIES Corporate Conferences, currently held four times a year at the Yale Club in New York City. EQUITIES is also the publisher of the renowned stock advisory newsletter -- EQUITIES Special Situations, which gained 14.78% verses 6.2% for the Wilshire 5000 Index in 2005; making this the fourth year in a row that the newsletter has substantially beaten the Index, according to The Hulbert Financial Digest.
To view the current issue of EQUITIES Magazine or our investor awareness programs, please go to our website at www.equitiesmagazine.com.
Safe Harbor -- This press release includes forward-looking statements that involve risks and uncertainties, including, but not limited to, product delivery, the management of growth, market acceptance of certain products and other risks. These forward-looking statements are made in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. For further information about these factors that could affect EQUITIES Global Communications, Inc. future results, please contact the Company directly. Prospective investors are cautioned that forward-looking statements are not guarantees of performance. Actual results may differ materially from management expectations.
Contact:
EQUITIES Global Communications, Inc.
EQUITIES Magazine
Jonathan Bernard
President/Director of Communications
310-575-4994
Email Contact
Email Contact
Optionen
0
0
0
0
Hier finden Sie Nachrichten zu Ihrem Suchbegriff - Sie können den Zeitraum angeben oder auch Suchbegriffe kombinierenErweiterte Suche | Do. 14.09.2006
§
Klicken Sie JETZT
§
Benutzername: § Anmelden
Passwort:
Klicken Sie JETZT
Business Wire · Aktuelle Nachrichten · Archiv< zurück < · Druckversion
13.09.2006 23:32
The Immune Response Corporation to Present at EQUITIES Magazine Transatlantic Corporate Conference; Company to Present in New York, London and Milan, September 15-20
Company's New York Presentation to Be Webcast 12:00 Noon EDT on September 15
The Immune Response (Nachrichten) Corporation (OTCBB:IMNR), an immuno-pharmaceutical company developing products to treat autoimmune and infectious diseases, announced it will be presenting at the EQUITIES Magazine Corporate Transatlantic Conference. President and CEO Dr. Joseph O'Neill will make presentations to sophisticated audiences of brokers, fund managers, investment professionals and active retail investors about the progress the Company has made since announcing its new corporate and clinical strategy last February. Dr. O'Neill's presentation will include updates on advances in the clinical programs of IRC's two lead immune-based therapies: NeuroVax(TM) for multiple sclerosis (MS) and IR103 for HIV/AIDS.
The EQUITIES Transatlantic Conference is scheduled for September 15, at the American Stock Exchange, New York City; September 18, at the AIM London Stock Exchange, London; and September 20, at the Borsa Italiana Stock Exchange, Milan.
The Immune Response Corporation's presentation will be webcast live on September 15, 12:00 noon EDT, from the New York City event.
In order to listen to the presentation and view the slides, use the following URL: http://www.visualwebcaster.com/equitiesmag/amex2006/event.html. To ensure you can access the presentation, please check the above URL early for web browser compatibility.
The presentation will also be archived for 90 days on the Company's website which you can access at: http://www.imnr.com/ir/ir_presentations.htm.
About The Immune Response Corporation
The Immune Response Corporation (OTCBB:IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
NeuroVax(TM), which is based on the Company's patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.
IR103 is based on the Company's patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company's first generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.
NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time. Please visit The Immune Response Corporation at www.imnr.com.
This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials. A more extensive set of risks is set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2005, and its subsequent Quarterly Reports filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.
Optionen
0
investitionsfachleuten und aktive Einzelkapitalanleger über den Fortschritt die Gesellschaft haben seit der Ankündigung seiner neuen korporativen und klinischen Strategie im letzten Februar gemacht. Die Präsentation von Dr O'Neill wird Aktualisierungen auf Fortschritten in den klinischen Programmen geschützt-basierter Leitungstherapien der zwei von IRC einschließen: NeuroVax (TM) für multiple Sklerose (FRAU) und IR103 für das HIV/AIDS.
Die AKTIEN Transatlantische Konferenz stehen zum 15. September, an der amerikanischen Börse, New York City auf dem Plan; am 18. September, am ZIEL Londoner Börse, London; und am 20. September, am Borsa Italiana Börse, Mailand. Die Geschützte Ansprechvereinigungspräsentation wird webcast lebend am 15. September, 12:00 Mittag EDT vom Ereignis von New York City sein.
Optionen
0
The Immune Response Corporation Announces Addition of James L. Foght, Ph.D., to Board of Directors
2006-09-15 09:30 ET - News Release
CARLSBAD, Calif. -- (Business Wire) -- Sept. 15, 2006
Company Website: http://www.imnr.com
The Immune Response Corporation (OTCBB:IMNR), an
immuno-pharmaceutical company developing products to treat autoimmune
and infectious diseases, announced today that James L. Foght, Ph.D.,
has joined the company's Board of Directors. Dr. Foght is Managing
Partner of Foght Enterprises, L.L.C., which is focused on
international business advisory services. He is also Managing Director
and a member of the investment committee of Vector Later-Stage Equity
Funds, specializing in investments in the life sciences.
"We are pleased to welcome Dr. Foght as a member of the board. His
scientific background along with his financial expertise will be an
important addition to our board as we advance the clinical programs of
IRC's two lead immune-based therapies: NeuroVax(TM) for multiple
sclerosis (MS) and IR103 for HIV/AIDS," said Dr. Joseph O'Neill,
President and Chief Executive Officer of The Immune Response
Corporation.
This February, The Immune Response Corporation announced a new
corporate and clinical strategy designed to position the company for
long-term success by accelerating the development of its most
promising immune-based therapies. Since then, significant progress has
been made against this new trajectory by raising substantial capital,
presenting promising clinical data for both the MS and HIV products,
and demonstrating dramatic yield improvements by their manufacturing
facility. Completion of the first stage of enrollment of the IR103
Phase II clinical trials was announced in June and the company is
poised to launch its Phase IIb trial for NeuroVax(TM) this fall.
"I am looking forward to working with the impressive management
and scientific teams at The Immune Response Corporation," said Dr.
Foght. "The company is investigating treatments in HIV and MS, two
devastating diseases with significant unmet medical needs."
Dr. Foght was formerly a Managing Director in the Investment
Banking division of Prudential Vector Healthcare Group, a unit of
Prudential Securities Incorporated. He joined Prudential in July 1999
with the acquisition of Vector Securities International, Inc., which
he co-founded in 1988.
Previously, Dr. Foght was Senior Vice President and Co-head of
Kidder Peabody's Life Sciences/Medical Products Specialty Group. Prior
to that, Dr. Foght spent 23 years with E.I. du Pont de Nemours & Co.,
spending half of his career in research and research management. He
became Managing Director of du Pont U.K. in 1979, with responsibility
for 4,000 employees and revenues of $700 million annually. In 1981,
Dr. Foght was responsible for the planning and implementation of a de
novo pharmaceutical business for du Pont in Europe, Africa, and the
Middle East. His responsibilities included managing clinical research,
regulatory affairs, licensing, manufacturing, and sales and
distribution from headquarters in Frankfurt, Germany. Later, Dr. Foght
established a worldwide Technology Evaluation and Acquisition Group
for du Pont in the life sciences area.
Dr. Foght earned his M.S. and Ph.D. in organic chemistry with
minors in biochemistry and microbiology from the University of
Illinois and holds a B.S. from the University of Akron.
About The Immune Response Corporation
The Immune Response Corporation (OTCBB:IMNR) is an
immuno-pharmaceutical company focused on developing products to treat
autoimmune and infectious diseases. The Company's lead immune-based
therapeutic product candidates are NeuroVax(TM) for the treatment of
MS and IR103 for the treatment of HIV infection. Both of these
therapies are in Phase II clinical development and are designed to
stimulate pathogen-specific immune responses aimed at slowing or
halting the rate of disease progression.
NeuroVax(TM), which is based on the Company's patented T-cell
receptor (TCR) peptide technology, has shown potential clinical value
in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown
to stimulate strong, disease-specific cell-mediated immunity in nearly
all patients treated and appears to work by enhancing levels of FOXP3+
Treg cells that are able to down regulate the activity of pathogenic
T-cells that cause MS. Increasing scientific findings have associated
diminished levels of FOXP3+ Treg cell responses with the pathogenesis
and progression of MS and other autoimmune diseases such as rheumatoid
arthritis (RA), psoriasis and Crohn's disease. In addition to MS, the
Company has open Investigational New Drug Applications (IND) with the
FDA for clinical evaluation of TCR peptide-based immune-based
therapies for RA and psoriasis.
IR103 is based on the Company's patented, whole-inactivated virus
technology, co-invented by Dr. Jonas Salk and indicated to be safe and
immunogenic in extensive clinical studies of REMUNE(R), the Company's
first generation HIV product candidate. IR103 is a more potent
formulation that combines its whole-inactivated antigen with a
synthetic Toll-like receptor (TLR-9) agonist to create enhanced
HIV-specific immune responses. The Company is currently testing IR103
in two Phase II clinical studies as a first-line treatment for
drug-naive HIV-infected individuals not yet eligible for
antiretroviral therapy according to current medical guidelines.
NeuroVax(TM) and IR103 are in clinical development by The Immune
Response Corporation and are not approved by any regulatory agencies
in any country at this time. Please visit The Immune Response
Corporation at www.imnr.com.
This news release contains forward-looking statements.
Forward-looking statements are often signaled by forms of words such
as should, could, will, might, plan, projection, forecast, expect,
guidance, potential and developing. Actual results could vary
materially from those expected due to a variety of risk factors,
including whether the Company will continue as a going concern and
successfully raise proceeds from financing activities sufficient to
fund operations and additional clinical trials of NeuroVax(TM)or
IR103, the uncertainty of successful completion of any such clinical
trials, the fact that the Company has not succeeded in commercializing
any drug, the risk that NeuroVax(TM)or IR103 might not prove to be
effective as either a therapeutic or preventive vaccine, whether
future trials will be conducted and whether the results of such trials
will coincide with the results of NeuroVax(TM)or IR103 in preclinical
trials and/or earlier clinical trials. A more extensive set of risks
is set forth in The Immune Response Corporation's SEC filings
including, but not limited to, its Annual Report on Form 10-K for the
year ended December 31, 2005, and its subsequent Quarterly Reports
filed on Form 10-Q. The Company undertakes no obligation to update the
results of these forward-looking statements to reflect events or
circumstances after today or to reflect the occurrence of
unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response
Corporation. NeuroVax(TM) is a trademark of The Immune Response
Corporation.
Contacts:
The Immune Response Corporation
Michael K. Green, 760-431-7080
info@imnr.com
or
Media Contact:
Chamberlain Communications Group Inc.
David Kyne, 212-884-0661
dkyne@chamberlainpr.com
or
Investor Contact:
ROI Associates
Robert Giordano, 212-495-0201
rgiordano@roiny.com
Optionen
0
Gruß Hausi
Optionen
0
kostet bestimmt auch viel aber wie du sagst einfach mal abwarten ,,
wenn es schon kleine sprünge macht freu ich mich auch
na ja liegen lassen und abwarten ändern können wir ja eh nichts !!
jetzt mal nächste woche abwarten da ist auch was angesagt silicon graphics da bin ich auch gespannt
aber schönes wochenende
gruss sesa
Optionen
1
0
2006-10-10 09:00 ET - News Release
CARLSBAD, Calif., Oct. 10 /PRNewswire-FirstCall/ -- The Immune Response Corporation today announced that it has entered into an agreement with Accelsiors CRO & Consultancy Services, a clinical research organization (CRO) with extensive experience in conducting multiple sclerosis (MS) trials, to oversee the 200-patient Phase II trial of NeuroVax(TM), an investigational T-cell receptor (TCR) peptide vaccine for the treatment of MS.
The Company further announced that this November in Budapest, Hungary, it will hold a clinical trial launch meeting with investigators participating in the trial and expects patient enrollment of the multi-center, randomized, double-blind trial to begin shortly thereafter. NeuroVax(TM) may represent a significant advance in the treatment of MS, which affects more than 2.5 million people worldwide, including more than 400,000 in the United States.
"We are extremely excited at the potential of NeuroVax(TM) to help patients with Multiple Sclerosis," said Krzysztof Selmaj, MD, PhD, Dept. of Neurology, Medical University of Lodz, Poland, Coordinating Investigator of the study. "This treatment may have the ability to alter how the immune system fights MS and we eagerly anticipate study results that could offer benefit to the millions of MS patients in need of more effective and tolerable treatment options."
The trial will enroll 200 patients with relapsing-remitting MS and will examine the effectiveness and safety of NeuroVax(TM) versus placebo. The primary objective of the study is to compare the cumulative number of new gadolinium enhancing lesions, a key marker of MS disease activity, using MRI scans at 24, 32, 40, and 48 weeks. Secondary objectives include additional MRI measurements, analysis of clinical relapses, measures of neurologic disability, immunologic evaluations, and safety.
The Company has also contracted with NeuroRx(R) Research, a company with special expertise in advanced MRI acquisition and analysis techniques, to oversee professional management of all MRI-related study activities.
"This trial is truly a watershed event for the Company, and potentially for the MS community as well," said Dr. Joseph O'Neill, President and CEO of The Immune Response Corporation. "We've made tremendous strides in building on the early NIH-funded research into NeuroVax(TM) and have now taken the critical steps necessary to launch a robust trial in multiple countries."
NeuroVax(TM), which is based on IRC's patented TCR peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. A recently published study showed that NeuroVax(TM) induced strong disease- specific cellular immunity in essentially all patients who received it. In addition, results from a one-year Phase I/II study, presented at this year's American Academy of Neurology annual meeting, showed that NeuroVax(TM) was able to restore normal levels of FOXP3+ Treg cells in patients who had statistically significant diminished levels compared to healthy controls (p<0.02). These Treg or regulatory T-cells appear to help control levels of pathogenic T-cells in MS patients.
MS is an autoimmune disease in which the immune system mistakenly attacks normal tissues of the central nervous system. The disease is caused by activation of a specific subset of the patient's own white blood cells, pathogenic T-cells, which then attack a fatty tissue called myelin that surrounds and protects nerve fibers and creates multiple areas of scarring (sclerosis) that interferes with the normal transmission of nerve impulses. This damage, in turn, leads to a variety of chronic, highly individual and unpredictable neurological symptoms, ranging from movement and balance problems to vision impairment.
By restoring healthy regulatory T-cell function, NeuroVax(TM) may offer a new and highly targeted mechanism to control pathogenic T-cell activity and limit or prevent nerve tissue damage in MS patients. Moreover, with a once a month dosing regimen and side effects that are so far limited to transient injection site reactions, NeuroVax(TM) could prove to be very easy for patients to tolerate compared to existing MS therapies.
About the Study
This trial is a multi-center, randomized, double-blind, placebo-controlled 48-week study to assess the safety and efficacy of NeuroVax(TM). Two hundred subjects with relapsing-remitting MS, with an Expanded Disability Status Scale (EDSS) score of less than or equal to 5.5 and meeting all inclusion/exclusion criteria, will be enrolled in the study in several Central and Eastern European countries including Belarus, Bulgaria, Poland, Russia, Serbia and Montenegro, Slovakia, and Ukraine. Clinical sites in these European countries have demonstrated themselves to be favorable locations for conducting efficient Phase II placebo-controlled MS studies by providing experienced clinical investigators, large patient populations and excellent MRI facilities.
Study participants will be randomized equally to receive either NeuroVax(TM) (100 microliters/mL of each of three T cell receptor peptides) or placebo (Incomplete Freund's Adjuvant) intramuscularly in the deltoid muscle every four weeks. Evaluation will occur every eight weeks by brain MRI scan and patients will also undergo evaluation by neurology examinations at 12, 24, 36, and 48 weeks. Safety will be monitored by routine physical exams that will be performed at 24 and 48 weeks, and lab tests of hematology, chemistry panel and urinalysis will be performed at weeks 4, 12, 24, 36, and 48.
About The Immune Response Corporation
The Immune Response Corporation is an immuno- pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate disease pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
NeuroVax(TM), which is based on the Company's patented T-cell receptor (TCR) peptide vaccine technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.
IR103 is based on the Company's patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company's first generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.
NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time. Please visit The Immune Response Corporation at www.imnr.com.
This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials. A more extensive set of risks is set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2005, and its subsequent Quarterly Reports filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.
Immune Response Corporation
CONTACT: Media Contact - Stacey Pfeffer of Chamberlain Communications
Group Inc., +1-212-884-0639, spfeffer@chamberlainpr.com; or Michael K.
Green, COO of The Immune Response Corporation, +1-760-431-7080,
info@imnr.com
Web site: http://www.imnr.com/
Optionen
0
die rakete startet und wir zu alten höhen in alten zeiten kommen
immune respo ist keine unbekannte firma ,und mit ihren 3 studien
alle in phase2 die rakteGEZÜNDET wird ...wenn das medikament wirkt!!!
mir reicht ja auch nur eine gute news wo den kurs wieder treibt ;-))
auch wenn der weg noch lange ist aber das ergebniss hoffe ich,mich vom hocker haut
aufjeden falll lege ich hier noch nach so günstig wie gerade wird man sie schon bald nicht mehr bekommen
aber ihr wisst ja nur meine meinung
?These exciting findings on the regulatory mechanism of how NeuroVax? can be influencing the pathogenic T-cells causing MS, coupled with our earlier MRI data that suggest NeuroVax? may decrease the number of total new Gadolinium enhancing lesions, are the basis for the design of a Phase II study that will be initiated later this year in Eastern Europe and the United States that will test the clinical benefit of NeuroVax? by assessing its effect on MRI and relapse rates.?
Dr. Joseph O?Neill,
President and CEO
§
§
§
By basing all our products on the immune system, which helps the body fight off diseases, we hope to develop long lasting solutions to difficult-to-treat diseases. The Immune Response Corporation is focused exclusively on development of effective therapies for people living with HIV and multiple sclerosis (MS).
The Immune Response Corporation is devoted to becoming one of the leading immune-based therapy companies in the world. A team of talented individuals work in partnership with reputable world-renowned universities to thoroughly research and develop medicines for HIV and MS patients who so desperately need them.
Following is an overview of the drug candidates currently in the pipeline, including their target indications and phase of clinical development. Due to the ever-changing nature of scientific research and clinical development, please refer to recent press releases for the most current information.
Please see our press releases for the latest clinical updates.
Click on the product name listed below for more information:
Therapeutic Area: Infectious Diseases
Compound Type Indication Phase
REMUNE® HIV-1 immunogen HIV infection II
IR103 HIV-1 immunogen with Amplivax? * HIV infection II
Therapeutic Area: Multiple Sclerosis
Compound Type Indication Phase
NeuroVax? T-cell receptor (TCR) peptide multiple sclerosis II
* Amplivax? is a trademark of Idera Pharmaceuticals, Inc.
PHASE I TRIALS:
Initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients. PHASE II TRIALS: Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. PHASE III TRIALS: Expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling.
